SOTIO, a biotech company based in Prague and Cambridge, MA, focuses on improving CAR-T therapies and stable antibody-drug conjugates (ADCs). In its poster presentation, SOTIO announced preclinical data on its immunocytokine SOT201 and the BOXR CAR-T cell therapy BOXR1030. The company’s focus, however, was on its oral presentation featuring SOT101.